SFJ I (Pfizer)

SFJ Pharmaceuticals I and Pfizer are conducting a late-stage trial of Pfizer's potential kidney cancer treatment axitinib. Usually drugs are launched in Japan and Asia several years after they have been launched in the US and other developed countries, limiting the therapeutic options available to physicians and patients. SFJ Pharmaceuticals I intends to reduce this delay.